Categories
- Active Surveillance
- Announcements
- Ask Dr. Barken
- Biomarker
- Biopsy
- Bone Metastases
- Brachytherapy
- Cancer Stem Cells
- Castration Resistant Prostate Cancer
- CETC
- Checklist
- Choline 11 PET Scan
- Clinical Trials
- Coaching
- Color Doppler Trans-Rectal Ultrasound
- Cryo Immunotherapy
- Cryoablation
- CTC
- Decision Making
- Diagnosis
- Exosome
- Ferumoxytol
- Focal Therapy
- Genome
- HIFU
- High Intensity Foucused Ultrasound
- Hormonal Blockade
- Hormone Refractory Disease
- Imaging
- Immune Therapy
- Intermittent Hormonal Blockade
- Journal Club
- Laser
- LIfe Style
- Liquid Biopsy
- Lymph Nodes
- Markers
- Metastatic Disease
- Metastatic Prostate Cancer Disease
- MRI
- MRI Guided Focal
- Multi Parameteric MRI
- Nutrition
- PCREF Support Group Meeting
- PET scans
- Photodynamic Therapy
- Prevention
- Prognosis
- Prostate Cancer
- PSA
- Radiation Therapy
- Radiation treatment
- Radical Prostatectomy
- Sequential Hormonal Blockade
- Sexual Dysfunction
- Support for Prosatate Cancer
- Survival prostate cancer
- Testosterone
- Theranostics
- Treatments for Prostate Cancer
- Tumor Spheres
- Uncategorized
- Vaccine
Category Archives: Prostate Cancer
Cryo Immunotherapy Part 2
Part 2 of the lecture about Cryo Immune Therapy given by Dr. Israel Barken from the Prostate Research and Education Foundation. Dr. Barken describes Cryo immunotherapy. The reasons why there are no consistent immune response after cryoablation are discussed. Suggestions … Continue reading
Cryoablation Immuno Therapy
Clinical Study Phase I Cryoimmunotherapy against Metastatic prostate Cancer Disease. Dr. Israel Barken, the Medical Director of the Prostate Cancer Research and Education, presents a clinical study phase I, featuring cryosurgery plus immuno-Modulator – Cyclophosphamide and Anti CTLA 4 Antibodies- … Continue reading
Percentage Involved Core Length and Risk of Recurrence After Radical Prostatectomy
Article: Greatest Percentage Involved Core Length and Risk of Clinically Significant Prostate-Specific Antigen Failure After Radical Prostatectomy. Author: Anthony V. D’Amico Source: Clinical Genitourinary Cancer. March 5, 2015
Circulating Epithelial Tumor Cells and Tumor Spheres
Circulating Epithelial Tumor Cells (CETC) and Tumor Spheres. Discussion with Prof. Katharina Pachmann, Ph.D, M.D who is the medical Doctor in Jena University Hopital’s Department of Experimental Hematology and Oncology. She is an expert on Circulating Epithelial Tumor Cells. The … Continue reading
New Prostate Cancer Immunotherapy- Prostvac
Dr. Barken introduces the New Prostate Cancer Immune Therapy for earlier stages of Prostate Cancer. Please watch the video below and see what he learned at the National Cancer Institute recent conference mentioned above. Dr. James Gulley explains the Prostvac … Continue reading
Posted in Clinical Trials, Immune Therapy, Prostate Cancer, PSA, Treatments for Prostate Cancer
Tagged PSA Only disease
Leave a comment
Enzalutamide and Prostvac for patients with PSA only disease after primary treatment
This very significant development could become the standard treatment for prostate cancer in the future. Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer. NIH Study- Recruiting- ClinicalTrials.gov Identifier: NCT01875250